Of note, the phase 1b study also reported synergistic anti-tumor responses with various chemotherapies, suggesting a molecular bias of certain tumors for HDAC6 inhibition which should be assessed further to determine if improved tumor microenvironment responses or direct cytotoxicity of the tumor cells are responsible. The gene discussed is HDAC6; the disease is neoplasm.